EUVIMEDEUVIMED entdecken
Fallbericht

How do we image patients with multiple myeloma and precursor states?

Rajshekhar Chakraborty iD, Jens Hillengass, Suzanne Lentzsch

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18880 ↗

Kurz gefasst

Fallbericht in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Rajshekhar Chakraborty und 2 weiteren Autor:innen. Beteiligte Einrichtung: Columbia University Irving Medical Center, New York, New York, USA. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advances in morphological and functional imaging have led to superior detection of early bone disease, bone marrow infiltration, paramedullary and extramedullary involvement in multiple myeloma. The two functional imaging modalities that are most widely used and standardized are 18F‐fluorodeoxyglucose–Positron emission tomography/computed tomography (FDG PET/CT) and whole‐body magnetic resonance imaging with diffusion‐weighted imaging (WB DW‐MRI). Both prospective and retrospective studies have demonstrated that WB DW‐MRI is more sensitive than PET/CT in the detection of baseline tumour burden and to assess response after therapy. In patients with smouldering multiple myeloma, WB DW‐MRI is now the preferred imaging modality to rule out two or more unequivocal lesions which would be considered a myeloma‐defining event by the updated international myeloma working group (IMWG) criteria. In addition to sensitive detection of baseline tumour burden, both PET/CT and WB DW‐MRI have been successfully used for monitoring response to therapy and provide information that is complementary to IMWG response assessment and bone marrow minimal residual disease. In this article, we present 3 vignettes illustrating how we approach the use of modern imaging in the management of patients with multiple myeloma and precursor states, with a specific focus on recent data that have emerged since the publication of the IMWG consensus guideline on imaging. We have utilized data from prospective and retrospective studies to provide a rationale for our approach to imaging in these clinical scenarios and highlighted knowledge gaps requiring future investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHumansPositron Emission Tomography Computed TomographyMagnetic Resonance ImagingDiffusion Magnetic Resonance ImagingProspective StudiesRetrospective StudiesWhole Body ImagingFluorodeoxyglucose F18Positron-Emission TomographyRadiopharmaceuticals

Stichwörter der Autor:innen

multiple myelomamyeloma MRIsmoldering myeloma

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Columbia University Irving Medical Center, New York, New York, USA.
  • Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.

ORCID-Profile: Rajshekhar Chakraborty

Zitieren

APA

Chakraborty, R., Hillengass, J., & Lentzsch, S. (2023). How do we image patients with multiple myeloma and precursor states?. British Journal of Haematology. https://doi.org/10.1111/bjh.18880

Vancouver

Chakraborty R, Hillengass J, Lentzsch S. How do we image patients with multiple myeloma and precursor states?. British Journal of Haematology. 2023. doi:10.1111/bjh.18880

BibTeX
@article{Chakraborty2023,
  author = {Chakraborty, Rajshekhar and Hillengass, Jens and Lentzsch, Suzanne},
  title = {How do we image patients with multiple myeloma and precursor states?},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18880}
}
Kostenlos starten →